No statistically significant differences were found in the relative values of the six immune-oncology biomarkers (CD3, CD4, CD8, CD68, FOXP3 and PD-L1) among the nine RCC samples, as shown in (Figure 3B). This evidence concerns the gene FOXP3 and renal cell carcinoma.